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Abstract 
Background: The aetiopathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP) is still unknown. The role 
of atopy and the concept of united airways in such patients are still a matter of debate. In this pilot study we aimed 
at evaluating the degree of eosinophilic inflammation and the frequency of atopy in a cohort of CRSwNP patients 
candidate for Functional Endoscopic Sinus Surgery (FESS) and assessing the association between these factors and 
relapsing forms of CRSwNP.
Methods: 30 patients (18 men, 12 women) with CRSwNP eligible for FESS were evaluated before and after surgery. 
Preoperative investigation included: history of previous relapse after FESS, clinical and laboratory allergologic assess‑
ment, spirometry, methacholine challenge, blood eosinophilia and determination of the fraction of nitric oxide in 
exhaled air (FeNO). Nasal fibroendoscopy, spirometry and FeNO determination were also assessed prospectively at 3 
and 27 months post‑FESS.
Results: 18/30 subjects were atopic, 6/18 (33 %) were monosensitized, 16/30 (53 %) were asthmatics and 10/30 
(33 %) had non steroidalantinflammatory drugs (NSAIDs) hypersensitivity. Twenty‑one patients (70 %) were classified 
as relapsers, 15/18 (83 %) among atopics, 6/12 (50 %) among non atopics (p = 0.05). Among patients with NSAIDs 
hypersensitivity, 9/10 (90 %) were relapsers. The median IgE concentration was 161.5 UI/mL in relapsers and 79 UI/mL 
in non‑relapsers (ns). The mean FeNO decreased after FESS (43.1–26.6 ppb) in 84 % of patients, but this effect disap‑
peared over time (FeNO = 37.7 ppb at 27 months). Higher levels of FeNO pre‑FESS were detected in atopics, and 
in particular in relapsing ones (median 51.1 ppb vs 22.1, ns). Higher levels of FeNO pre‑FESS were detected in asth‑
matic patients, especially in those who relapsed (median: 67 vs 64.85 ppb in non‑relapsed patients, ns). The Tiffeneau 
Index (FEV1/FVC) was significantly lower in asthmatic relapsers than in non relapsers asthmatics (94.7 ± 11.1 versus 
105 ± 5.9—p = 0.04). Patients with asthma and atopy had a major risk of relapse (p = 0.05).
Conclusion: In our pilot study, atopy, severe asthma, bronchial inflammation, NSAIDs hypersensitivity and high level 
of total IgE are possible useful prognostic factors for the proneness to relapse after FESS. The role of allergy in CRSwNP 
pathogenesis should consequently be given deeper consideration. Allergen specific immunotherapy, combined with 
anti‑IgE therapy, may have an immunomodulatory effect preventing polyps relapse and need to be investigated.
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Background
Chronic rhinosinusitis (CRS) affects approximately 
5–15 % of the general population both in Europe and the 
USA, ranking this condition second in prevalence among 
all chronic conditions [1–3]. Only a fraction of CRS 
patients develop nasal polyps (NP), suggesting that nasal 
inflammation could follow different pathogenic path-
ways. The reported prevalence of NP is 2.7 % in popula-
tion-based studies [4]. NP occur in all races with a slight 
male preponderance (male to female ratio  =  2.2:1) [5] 
and with an increased frequency in asthmatics. Besides 
congenital subtypes (e.g. those secondary to cystic fibro-
sis), most forms of NP have their onset in the early adult-
hood [6–9]. However, all age groups are involved and the 
prevalence of the disease grows with age.
Little is known about the pathogenesis of CRS with 
or without NP (CRSwNP and CRSnNP respectively). 
As a consequence, most patients are classified as hav-
ing idiopathic CRS in the daily clinical practice. Indeed 
chronic inflammation of the mucosa of the nose and 
paranasal sinuses develops in almost all cases, maybe as 
the evolution of acute rhinosinusitis (especially in cases 
of CRSnNP). According to the current pathogenic para-
digm, genetic susceptibility [10, 11] and environmen-
tal triggers probably concur to the failure of the normal 
immunological surveillance at the level of the airway 
mucosa and to the development of aberrant immune 
responses against unknown allergens/antigens [12]. In 
particular, chronic bacterial colonization of the res-
piratory mucosa is thought to promote IgE production 
through superantigen stimulation [12, 13] and subse-
quently to enhance the degranulation of mast cells within 
the polyps [14]. This phenomenon would explain the 
known discrepancy between the high local expression 
of IgE in the mucosa of asthmatic and CRSwNP (but not 
CRSnNP) patients and the poor correlation of this find-
ing with serum IgE concentrations and skin prick test 
results [15].
The prognosis of CRS is worse in CRSwNP than 
in CRSnNP, especially if the patient is suffering also 
from asthma and non steroidalantinflammatory drugs 
(NSAIDs) hypersensitivity [16, 17]. CRSwNP is in fact 
characterized by invalidating symptoms, that alter 
patient quality of life. Furthermore the rate of post-sur-
gical recurrence is high (60  %) in these patients, when 
compared to patients with CRSnNP. However, affordable 
markers of disease activity and predictors of relapse are 
not yet available for the Clinician to date.
We thus aimed at identifying possible associations 
between a panel of clinical, laboratory and functional 
markers of atopy and eosinophilic inflammation and the 




30 CRSwNP patients, aged 18–75  years and candidate 
to FESS were consecutively enrolled. The study was 
approved by the Ethical Committee of the SanRaffaele 
Hospital (Milan, Italy) and all subjects signed informed 
consent. CRSwNP was diagnosed by fibroscopy and 
CT scan without contrast media. Fourteen patients had 
already undergone FESS in the past. Patients with pre-
vious relapses and patients with evidence of relapse 
at 27  months were all included in the “relapsers’” sub-
group. Exclusion criteria were represented by associated 
congenital diseases (Cystic fibrosis), granulomatous or 
vasculitic diseases (Sarcoidosis, Granulomatosis with Pol-
yangiitis, Eosinophilic Granulomatosis with Polyangiitis).
Clinical, laboratory and functional assessments 
included:
 – Allergy assessment: Clinical history: exposure to envi-
ronmental agents: occupational agents, pets, smoke, 
familiarity for allergic diseases, asthma, rhinosinusi-
tis, autoimmune diseases. Past allergic clinical his-
tory: rhinocongiuntivitis, rhinosinusitis, asthma, drug 
hypersensitivity, food allergy. Allergy tests already 
performed. Extra-allergic clinical history and current 
medical/surgical treatment were also assessed. All 
patients underwent skin prick tests (SPTs) for common 
aeroallergens (house dust mites, mould (Alternaria, 
Cladosporium, Aspergillus), pollens (Hazel, Alder, 
Birch, Cypress, Grass, Olive, Parietaria, Mugwort and 
Ragweed), latex and cat and pet dander as previously 
described [18].
  – Laboratory assessments: all patients underwent a 
complete blood count, erythrosedimentation rate 
(ESR), C-reactive protein (CRP), protein electrophore-
sis, antinuclear antibodies, anti-neutrophil cytoplasmic 
antibody, total and specific IgE for the aeroallergens 
panel previously described for SPTs, in case of nega-
tive in vivo tests. Blood hypereosinophilia was defined 
as eosinophils >500/mm3. Patients were classified as 
atopic when SPT and/or specific IgE were positive to at 
least one common aeroallergen.
  – Lung function test: Spirometry: lung function tests 
were performed using the standard protocols accord-
ing to the American Thoracic Society and the Euro-
pean Respiratory Society (ATS/ERS) guidelines [19]. 
Forced expiratory volume in 1  s (FEV1) and vital 
capacity (VC) were expressed as a percentage of pre-
dicted value. Tiffeneau index (TI) is the ratio of FEV1/
forced vital capacity (FVC), used in the diagnosis of 
obstructive airways diseases. Asthmatic patients were 
receiving a standard long-term control medication 
for asthma. Methacholine challenge was performed 
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to assess aspecific bronchial hyper reactivity and was 
made according to the ATS/ERS guidelines in patients 
without a previous asthma diagnosis and with a nor-
mal spirometry at baseline.
  – Offline measurement of the fraction of nitric oxide 
(NO) in exhaled air (FeNO). This procedure was per-
formed according to the ATS/ERS guidelines [20].
Timing
Patients were first evaluated 3  months after FESS by 
performing: (1) Ear, nose and throat (ENT) visit with 
fibroendoscopy. (2) Allergy visit. (3) Complete blood 
count. (4) Determination of FeNO in exhaled air. (5) 
Lung function test. At 27  months patients were re-
evaluated through (1) ENT visit with fibroendoscopy. 
(2) Allergy visit and (3) determination of FeNO in 
exhaled air.
Statistics
Data are presented as mean  ±  standard deviation (SD) 
or median ±  IQR. For group comparisons, we used the 
Mann–Whitney U test. Categorical variables were com-
pared with the Fisher’s exact test. P values less than 0.05 
were considered statistically significant. Relative risk for 
relapse of CRSwNP co-morbidities was also calculated.
Results
The clinical features of the 30 CRSWNP patients (19 
males, 11 females) are shown in Table  1. Eighteen 
patients were atopic (11 of them newly diagnosed), 
16/30 were asthmatics (9 of them newly diagnosed) 
and 10/30 had NSAIDs hypersensitivity. Fourteen 
patients (47  %) had a history of at least one previous 
relapse after FESS whereas 16/30 (53  %) were at their 
first surgery. Twenty-one patients (70  %) experienced 
relapse during their disease history (7/21 relapses 
occurred during the 27 ± 7 months period of prospec-
tive observation).
Allergological parameters and association of atopy 
with relapse
The detailed description of allergycharacteristics of the 
30 CRSWNP patients are shown in Additional file  1: 
Table S1. Eighteen patients (60 %) were atopic: 15 relaps-
ers (83 %) and 3 non relapsers (p = 0.05, RR: 5, IC: 0.93–
26.78) Fig.  1. Six out of 18 atopic patients (33  %) were 
monosensitized, whereas 12 (67 %) polysensitized. Three 
out of 18 (16.6 %) were sensitized to a seasonal allergen, 
whereas 15/18 (83.4  %) were sensitized also to a peren-
nial allergen (house dust mites, moulds and/or pets dan-
der). The median IgE concentration was higher in atopic, 
in particular in relapsers (Median: 161.5 UI/mL in relaps-
ersversus 79  UI/mL in non-relapsers, ns), as showed in 
Fig. 2. Three subjects had high level of total IgE, without 
a sensitization to common aeroallergens. Two of them 
relapsed after surgery.
Asthma
We found that 16/30 (53  %) patients were asthmatics. 
The diagnosis of asthma was made for the first time with 
us in 9 out of 16 asthmatic patients (56 %) of our group. 
Among asthmatics 13/16 (81  %) were relapsers (ns). 
The phenotype of CRSwNP patients with both asthma 
and atopy was more associated with relapsing forms of 
CRSwNP (p = 0.05).
Table 1 clinical characteristics of the study population
Clinical parameter N (%)
Males/females 19/11
Mean age (years) 52 ± 11.6
Family history for allergic diseases 11/30 (37 %)
Atopy (prick test and specific IgE to common aeroallergens) 18/30 (60 %)
 New diagnosis 11/18 (61 %)
Asthma 16/30 (53 %)
 New diagnosis 9/16 (56 %)
NSAIDs hypersensitivity 10/30 (33 %)
Relapsing forms 21/30 (70 %)
Blood hypereosinophilia before FESS 10/29 (34 %)
Fig. 1 Frequency of atopy in relapsers: there was a trend of relapse in 






















Fig. 2 IgE levels considering atopy and relapse: higher levels of IgE 
were detected in atopics, in particular in relapsed ones.
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Markers of eosinophilic inflammation
Eight out of 21 relapsers (38  %) had increased blood 
eosinophilia versus 2/9 (22 %) non-relapsers (ns). Nitric 
oxide in exhaled air (FeNO) was evaluated both in asth-
matics/non asthmatics and atopics/non atopics (Table 2). 
High levels of FeNO (>25 ppb) were detected in 50 % of 
patients at baseline and at the end of the follow-up. More 
than 50 % of patients had high levels of FeNO (>25 ppb) 
at baseline and at the end of the follow up. The mean 
FeNO decreased after FESS (43.1–26.6  ppb) in 84  % of 
patients who performed the analysis both before and 
after FESS (Fig. 3). However after 27 ± 7 months higher 
levels of FeNO were again detected (FeNO  =  37.7  ppb 
at 27  months; Fig.  3). Higher levels of FeNO pre-FESS 
were detected in atopic (median: 30.10 vs 24.85  ppb 
in non atopic patients ns), and in particular in relapsed 
atopics versus non relapsed ones (median 51.1 ppb vs 
22.1, ns). Higher levels of FeNO pre-FESS were detected 
inasthmatic patients (median FeNo levels 67 vs 19.2 ppb 
in non asthmatic patients; p = 0.05), especially in those 
who relapsed (median: 67 vs 64.85  ppb in non-relapsed 
patients, ns) (Figs. 4, 5).
Respiratory function tests
The Tiffeneau Index (FEV1/FVC) was significantly lower 
in asthmatic relapsers than in non relapsers asthmat-
ics (94.7 ±  11.1 versus 105 ±  5.9—p =  0.04). Also FEV 
1 showed a worse trend in relapsers, when compared to 
non relapsers (3.07L, 96.7 % pred versus 3.7, 103 % pred, 
ns).
Discussion
Identifying pathogenic factors involved in the devel-
opment of NP and clinical markers of post-surgical 
relapse are still important unmet needs in the ENT/
allergological practice. Here we described a cohort of 
patients with CRSwNP undergoing FESS and we evalu-
ated clinical, laboratory and functional parameters dur-
ing the course of the disease and in a short prospective 
period.
Persistent and symptomatic inflammation of the nasal 
mucosa and paranasal sinuses characterize CRSwNP 
as part of a complex pathophysiological continuum of 
eosinophilic inflammation involving both the upper and 
lower respiratory tract (United Airways Disease) [21]. 
Table 2 Percentage of patients with high FeNO (>25 ppb)









54.5 % 31 % 54 %
Non‑asthmatic 33 % 37.5 % 43 %
Non‑atopic 42 % 37.5 % 36 %
Asthmatic 67 % 62.5 57 %
Atopic 58 % 62.5 64 %
Fig. 3 Timecourse of FeNO at baseline and at the short and long‑
term follow‑up: the mean FeNO decreased after FESS (43.1–26.6 ppb) 
in 84 % of patients who performed the analysis both before and after 
FESS. However after 27 ± 7 months higher levels of FeNO were again 























Fig. 4 FeNO levels before surgery in atopic and non‑atopic patients: 
higher levels of FeNO pre‑FESS were detected in atopics, and in 






















Fig. 5 FeNO levels before surgery in asthmatic and non‑asthmatic 
patients: higher levels of FeNO pre‑FESS were detected in asthmatics, 
and in particular in relapsed ones.
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NSAIDs hypersensitivity and asthma are also part of this 
pathological process and show strong epidemiological 
and pathogenic associations with CRSwNP [9, 22, 23]. 
In particular, the severity of asthma has been linked with 
the risk of relapse in patients with CRSwNP, while surgi-
cal treatment of NP ameliorated functional parameters in 
asthmatic patients [24].
Here, we showed that FeNO levels, which better cor-
relate with the degree of eosinophilic inflammation at 
the level of the (lower) airways, were higher in asthmatic 
patients and relapsers. FeNO levels readily decreased 
after FESS in CRSwNP. Thus, in addition to previous 
reports describing an improvement in asthma symptoms 
and in peak expiratory flow rate [24], we provide an indi-
rect evidence that immunological responses occurring 
at the level of the higher airways are required to sustain 
inflammation in the lower part of the respiratory tract, in 
accordance with the United Airways Disease hypothesis 
[21].
According to the literature, there is a weak associa-
tion between atopy and the risk of NP development and 
relapse [9, 22, 23]. Consequently, allergy testing are not 
included in the flowchart of CRSWNP patients sug-
gested by EPOS guidelines [1]. However, local derange-
ment of the immune function towards aberrant IgE 
responses contributes to the maintenance of inflamma-
tion in CRSwNP [25]. Accordingly, anti-IgE therapeutic 
regimens showed efficacy in preventing NP relapses [26] 
and in the treatment of recalcitrant forms of NP associ-
ated with asthma [27, 28]. In this setting, the potential 
role of systemically deranged IgE responses (i.e. atopy) is 
still debated [25, 29–31]. In our small set of patients with 
CRSwNP, atopy shows a high prevalence, possibly due to 
a selection bias towards more severe forms of CRSwNP, 
frequently associated with comorbidities, in particular 
asthma, NSAIDs hypersensitivity and atopy, sometimes 
accompanied by clinically significant respiratory symp-
toms. We also observed an association between NP 
relapse and atopy, and this association was confirmed in 
patients with allergic asthma. In accordance to a promi-
nent role of local IgE response in the pathogenesis of 
CRSwNP, circulating levels of IgE were higher in relaps-
ing forms of CRSwNP.
Chronic rinonasal inflammation could be supported 
by an aberrant response against exogenous well known 
aeroallergens (house dust mites, fungi) [31] or develop as 
the result of superantigen (e.g. from S. aureus) stimula-
tion [12]. Along with this line, we could hypothesize that 
specific immunotherapy (SIT) could prove beneficial in 
CRSWNP. However, few studies investigated the associa-
tion between sensitization to aeroallergens and NPs, and 
even fewer tested the efficacy of SIT in the treatment of 
CRSWNP and prevention of relapse after FESS surgery. 
In particular the only large trial published to date [32] 
reported no benefit with the use of SIT with respect to 
NP relapse. However, that study was strongly limited by 
the short period of SIT administration.
Conclusions
CRSWNP could be associated with atopy, clinical 
allergy, asthma and NSAIDs hypersensitivity. Patients 
with CRSwNP need therefore to be evaluated by mean 
of a multidisciplinary approach. Our data suggest that 
the phenotype of patients with both asthma and atopy 
is associated with relapsing forms of CRSwNP. Patients 
with CRSWNP show also signs of aberrant IgE responses 
and eosinophilic inflammation. Local inflammation of 
the upper respiratory tract seems to contribute to the 
maintenance of inflammation at the level of lower air-
ways. On the other hand, local indices of eosinophilic 
inflammation and aberrant IgE response do not corre-
late with the corresponding systemic counterparts and 
are probably more accurate as markers of disease and 
maybe as predictors of relapse in CRSWNP. More studies 
are required to confirm the link between atopy allergic 
asthma and relapsing forms of CRSwNP.
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